Background: Although certain opioid analgesics have immunosuppressive properties and increase the risk for infections in animals, the clinical effects of prescription opioid use on infection risk among humans are unknown.
A s opioid analgesic use has increased in the United States, the safety of prescription opioids has come under further scrutiny (1) (2) (3) (4) . Common safety concerns include the potential for opioid use disorders, overdose, and serious adverse respiratory and cardiovascular events (5) (6) (7) (8) . However, these known adverse effects only partially account for the excess morbidity and mortality observed among prescription opioid users (9 -11). Although concern has been expressed regarding a potential excess of infections observed among prescription opioid users, few studies have attempted to quantify the risk for infection in this group (12) (13) (14) .
Certain opioids have known immunosuppressive properties, and their use may increase the risk for infections (15, 16). Animal and in vitro experimental studies have demonstrated that some opioids disrupt lymphocyte and phagocyte proliferation, reduce innate immune cell activity, and inhibit cytokine expression and antibody production (16 -18) . In animal models, opioidinduced immune disruption also led to increased susceptibility to bacterial infections, including those caused by common human pathogens, such as Streptococcus pneumoniae (19 -21). However, the clinical implications of these observations for humans, including whether the risk differs by specific opioid properties or dosage, remain unclear.
Invasive pneumococcal disease (IPD), caused by S pneumoniae, includes serious illnesses, such as bacteremia, meningitis, and invasive pneumonia (22). The case-fatality rate for IPD is high among adults (pneumonia, 5% to 7%; bacteremia, 20%; meningitis, 22%) and thought to be even higher among older persons (23). Diagnosis of IPD requires the isolation of S pneumoniae from a normally sterile site (23). Known risk factors for IPD include age (young children and older adults are more susceptible), decreased immune function, chronic high-risk medical conditions (such as lung, liver, and kidney disease), and cigarette smoking (22, 24 -26) . Because IPD monitoring and prevention remain a public health priority, and opioid analgesic use represents a potentially novel and modifiable risk factor for serious infections-including IPD-we sought to test the hypothesis that opioid analgesic use is an independent risk factor for laboratory-confirmed IPD.
managed Medicaid program in Tennessee. TennCare provides health care insurance to Tennessee residents who are Medicaid eligible. TennCare data provided information on enrollment, demographic characteristics, pharmacy use, health care encounters, and comorbid conditions for each participant. These data were supplemented with state vital records information and hospital-based data from the Tennessee Hospital Discharge Data System. Pharmacy data were supplemented with Medicare Part D information for dualeligible participants. Laboratory-confirmed IPD cases were identified from the Tennessee Active Bacterial Core surveillance (ABCs) system. The ABCs system is funded by the Centers for Disease Control and Prevention to conduct active population-and laboratorybased surveillance in 10 states for disease due to selected pathogens of public health relevance, including IPD (27). In Tennessee, Vanderbilt University Medical Center collaborates with the Tennessee Department of Health and Tennessee Emerging Infections program to operate the ABCs system in 20 counties. The system collects demographic, health care encounter, risk factor, and specimen or pathogen information for every detected case.
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Study Cohort
All TennCare enrollees who had filled at least 1 study opioid prescription from 1995 to 2014 were identified (see "Exposure") to exclude persons with contraindications to opioids and those who may not have been eligible to receive these drugs. The participants entered the study cohort on the earliest date (t 0 ) that a study opioid prescription was filled. Inclusion criteria were continuous enrollment in TennCare for at least 365 days prior to t 0 , age 5 years or older, documented access to pharmacy benefits, more than 1 health care encounter and no IPD identified during baseline, and absence of nonstudy opioid prescriptions (see "Exposure") during baseline or on t 0 . Participants also were required to have resided for at least 1 day during the study period in a Tennessee county that reported to the ABCs system (see "Case-Control Selection"). Follow-up continued from t 0 through the earliest of the following: the end of the study (31 December 2014), death, loss of enrollment, IPD, or first nonstudy opioid use. Participants who ended follow-up because of loss of enrollment, IPD, or nonstudy opioid use were allowed to reenter the cohort if they subsequently fulfilled all eligibility criteria.
Case-Control Selection
We used the ABCs system to identify laboratoryconfirmed IPD among cohort members. Invasive pneumococcal disease was defined by the isolation of S pneumoniae from a normally sterile site (such as blood or cerebrospinal fluid) (24). The sample collection date was the index date for each case. We used incidence density sampling to randomly select up to 20 cohort members at risk but without laboratory-confirmed IPD (control participants) per case patient. Control participants were matched to case patients by index date as well as by age (individual years) and county of residence on that date. A study participant could serve as a control participant for several case patients and could later become a case patient. Although nested casecontrol and cohort designs would provide the same conclusions, the former was preferred for efficiency, especially with regard to exposure and covariate classification. Classifications were done relative to the index date, which simplifies the extensive computational challenge of tracking time-varying exposure and No 4.0 HCL = hydrochloride; MME = morphine milligram equivalents. * Opioid characteristics were defined on the basis of the previous literature and classifications used in earlier studies (7, 13, 14, 30). † Conversion per milligram of opioid, with conversion factors based on classifications used in earlier studies (7, 13, 14, 30). To convert to MME, multiply by the strength of the opioid per day by the conversion factor. ‡ Alone or in combination. § In combination. ͉͉ The conversion factor to MME assumes that the opioid strength is measured in milligrams per oral dose and assumes 50% bioavailability of transmucosal fentanyl (e.g., 0.100 g of transmucosal fentanyl is equivalent to 12.5 mg of oral morphine) (7). ¶ The conversion factor to MME assumes that the opioid strength is measured in micrograms per hour and that each patch remains in place for 3 d (e.g., transdermal fentanyl, 25 mcg/h, is equivalent to oral morphine, 60 mg/d (7). 
Exposure
The use of prescribed study opioids, either oral or transdermal, was the exposure of interest. Nonstudy opioids included antitussive and antidiarrheal agents (for nonpain indications); injectable formulations, for which timing of use and dosage may be difficult to ascertain; and drugs used primarily for opioid use disorders (such as buprenorphine). Using pharmacy data, we defined 4 mutually exclusive exposure categories relative to the index date for case patients and control participants. Current users were those with a study opioid prescription overlapping the index date. To minimize exposure misclassification due to imperfect adherence or intermittent use, recent users were those whose most recent prescription ended 1 to 90 days before the index date and past users were those whose most recent prescription ended 91 to 182 days before the index date. Remote users included persons in all other scenarios without an opioid prescription that ended within 182 days before the index date. New users were defined as a subset of current users whose prescription overlapping the index date was initiated after 182 days without an opioid prescription. Current opioid use, the main study exposure, was classified further according to the drug's duration of action (short or long), potency (moderate or high), previously described immunosuppressive properties (immunosuppressive, nonimmunosuppressive, or unknown), and estimated daily dose in morphine milligram equivalents (MME) on the index date (<50, 50 to 90, or ≥90 mg). Opioid characteristics were defined at the national drug classification code level of the agent on the basis of the previous literature and classifications used in earlier studies (Table 1) (7, 13, 14, 30). To avoid misclassification, current users of more than 1 opioid type were classified separately from those receiving only a single type.
Covariates
Relevant demographic characteristics, comorbid conditions (including IPD risk factors), conditions associated with pain, medication use, and health care use were measured during the 365 days before the index date and considered as potential confounders. Demographic characteristics included sex and race. Other covariates, including use of health care resources, were defined by using diagnosis and procedure codes. Well-recognized risk factors for IPD, according to the Advisory Committee on Immunization Practices, included alcohol or substance use disorder, cardiovascular disease, serious hepatic or chronic lung disease, end-stage renal disease or hemodialysis, HIV, cancer, immune disorders, diabetes, sickle cell disease, and tobacco smoking (25, 26). Other comorbid conditions included surrogate frailty markers (such as debility, pressure ulcers, and impaired mobility) (31). Conditions associated with pain included abdominal, back, musculoskeletal, dental, and neuropathic pain, as well as trauma or injury, headache, arthritis, and pain not otherwise specified. Health care use included nursing home residence and the baseline number of hospitalizations and outpatient and emergency department visits (Appendix Table 1 , available at Annals.org). On the basis of our selection criteria, only persons with full benefits who demonstrated active use of those services were included. Thus, indicators for each study covariate were based on the presence of specific conditions and medication use. Lack of evidence meant the individual had no history of that condition or medication use, so this information was not considered missing.
Statistical Analysis
We compared the odds of being a current versus a remote opioid user between case patients and control participants. Multivariable conditional logistic regression was used to calculate adjusted ORs (aORs) and Table 1) . † Control participants were matched to case patients by age, county of residence, and eligibility on the index date (i.e., control participants had to be eligible retrospective cohort members on the index date for the case). ‡ Each opioid was categorized a priori as potentially IS, NIS, or unknown on the basis of existing literature ( Table 1) . § Categories were defined a priori according to MME per day on the basis of categories outlined in the Centers for Disease Control and Prevention chronic pain opioid prescribing guidelines, which recommend careful assessment of opioid prescriptions between 50 and 90 MME/d and ≥90 MME/d (7).
Opioid Use and Invasive Pneumococcal Disease Risk ORIGINAL RESEARCH 95% CIs, accounting for the matching design and adjusting for all well-recognized risk factors for IPD. To assess model fit and fulfillment of assumptions, we conducted standard regression diagnostics for conditional logistic regression (Appendix, Section 3, available at Annals.org) (32). Planned secondary analyses stratified current opioid use in separate models by duration of action, potency, previously described immunosuppressive properties, and estimated daily dose (7, 13, 14, 30). Because opioid-related respiratory depression may facilitate aspiration and the development of pneumonia, we also assessed IPD associated with pneumonia separately from nonpneumonia IPD outcomes.
As a complementary method of assuring that current and remote opioid users were similar with regard to IPD risk, we conducted a separate, planned analysis by calculating an IPD risk score that included all study covariates, excluding the well-recognized risk factors for IPD (Appendix Table 2 , available at Annals.org). Analogous to propensity scores for cohort studies, disease risk scores provide an efficient strategy to account for potential differences in the risk for IPD between exposure groups in case-control designs, especially when the number of covariates is large, the exposure consists of several categories, and the number of cases is limited (33-35). The IPD risk score was calculated among all noncurrent opioid users by using a logistic regression model with IPD as the outcome and included 103 covariates assessed in the 365 days preceding the index date. The coefficients from this logistic regression model were used to calculate the predicted probability of IPD for each person in the entire study population independent of opioid exposure and the presence of IPD risk factors. We incorporated the IPD risk score, categorized as deciles of predictive probabilities, together with the well-recognized IPD risk factors into the conditional logistic regression model for opioid use and IPD (33).
Because opioids sometimes are prescribed for the initial clinical manifestations of IPD (such as chest pain associated with pneumonia), a planned sensitivity analysis excluded new users who began opioid treatment within 4 days (inclusive) of the index date to address possible protopathic bias. Our primary analysis accounted for receipt of the pneumococcal polysaccharide vaccine in the 365 days before the index date. Because polysaccharide vaccine protects against IPD for at least 5 years (25), we examined pneumococcal vaccination history among case patients and control participants who were continuously enrolled in TennCare for at least 5 years preceding their index date. Because pneumococcal conjugate vaccines (PCVs) also provide long-term protection against IPD, we repeated our main analysis excluding data from 2012 to 2014, when PCV was recommended for use in adults (25, 26). Finally, we assessed the sensitivity of our estimates to the effect of a potential unmeasured confounder (36). All analyses were performed in Stata/IC, version 15.1 (StataCorp). 
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RESULTS
Study Population
From the retrospective cohort of TennCare enrollees who fulfilled all selection criteria (n = 221 096) (Appendix Figure 1 , available at Annals.org), we identified 1233 patients with laboratory-confirmed IPD (73.9% of the cases [n = 911] were invasive pneumonia) and 24 399 matched control participants. The case group had a lower percentage of females and a higher prevalence of risk factors for IPD, including cardiovascular and chronic lung disease, HIV, cancer, and tobacco smoking compared with the control group. In addition, 25.2% of the case patients were current opioid users on the index date, compared with 14.4% of the control participants ( Table 2) . Among current opioid users, a larger percentage of those in the case than the control group used long-acting and high-potency opioids as well as higher daily doses ( Table 3) . A comparison of characteristics between exposure groups showed that current opioid users had a higher prevalence of IPD risk factors than remote users, including an age of 40 years or older, cardiovascular and chronic lung disease, cancer, diabetes, and tobacco smoking, as well as a greater level of previous health care use. Pneumococcal polysaccharide vaccination in the 365 days before the index date was more common among current than remote users ( Table 4) .
Opioid Use and Risk for IPD
Compared with remote opioid use, current use was statistically significantly associated with IPD in the multivariable conditional logistic regression model, which adjusted for well-known IPD risk factors (aOR, 1.62 IPD = invasive pneumococcal disease; IS = immunosuppressive; MME = morphine milligram equivalents; NIS = nonimmunosuppressive. * Each set of opioid characteristics (recency, duration of action, immunosuppression, potency, and dose) was examined by using a separate conditional logistic regression model that included the same covariate sets (Appendix Table 4 , available at Annals.org). † Derived from the full model-including sex, race, alcohol/substance use disorder, cardiovascular disease, serious hepatic disease, chronic lung disease, hemodialysis, HIV, cancer, immune disorders, diabetes, sickle cell disease, smoking and smoking-related diagnoses, nursing home residency, pneumococcal polysaccharide vaccination, and numbers of health care encounters (hospitalizations and emergency department and outpatient visits)-taking into account the study design, in which control participants were matched to case patients by age, county of residence, and eligibility on the index date (i.e., control participants had to be eligible members of the retrospective cohort on the index date for the case). ‡ Subset of current users. § Categories were defined a priori according to MME per day on the basis of categories outlined in the Centers for Disease Control and Prevention chronic pain opioid prescribing guidelines, which recommend careful assessment of opioid prescriptions between 50 and 90 MME/d and ≥90 MME/d (7). Table 5 ).
The IPD risk score was calculated among noncurrent users (n = 20 878 control participants; n = 922 case patients) (Appendix Table 2 ). Including the IPD risk score in the model yielded results that were very similar (aOR, 1.61 [CI, 1.35 to 1.91]) (Appendix Table 5 , available at Annals.org) to the main analysis findings.
Sensitivity Analyses
In the planned sensitivity analysis that excluded case patients and control participants with an index date in the first 4 days of new use, the aOR for current users was relatively unchanged from the main analysis In a quantitative analysis to determine the sensitivity of our findings to a potential unmeasured confounder, we estimated that an unknown confounder would need to be an independent, strong risk factor for IPD with an OR of 2 or greater and to have an absolute difference in prevalence of more than 35% between current and remote opioid users to explain the observed lower CI bound of the aOR (1.36) from our primary analysis (Appendix Figure 2 , available at Annals .org). At lower absolute differences in prevalence (25%, 15%, and 10%), the unknown confounder would have to be a stronger, independent risk factor for IPD (ORs of 2.5, 3.5, and 5.5, respectively). Of note, none of the covariates in the study (including all IPD risk factors and pneumococcal vaccination history) met such requirements for the absolute difference in prevalence and the strength of the independent association ( Table 4 and  Appendix Table 3 ). Therefore, weaker confounders and those with lower exposure prevalence differences could partially attenuate the observed association, but not fully account for it.
In the examination of pneumococcal polysaccharide vaccination history among case patients and control participants with at least 5 years of continuous enrollment before the index date, the vaccination rate was higher in the case than the control group (14.9% vs. 10.1%; n = 18 354) and among current versus remote opioid users (16.4% vs. 8.5%). Therefore, because of the protective effect of polysaccharide vaccination, the differences in polysaccharide vaccination history observed in the study population could not explain our findings, and our estimates may be conservative. Likewise, excluding persons with an index date in years when PCVs were recommended for adults (n = 23 065) yielded results similar to the main findings (aOR, 1.64 [CI, 1.36 to 1.97]).
DISCUSSION
We report a strong association between the use of prescribed opioids and the risk for laboratoryconfirmed IPD. The association was strongest for current users of formulations that are long acting, high potency, previously described as immunosuppressive, and taken in high doses, and was consistent across clinical syndromes of IPD.
The immunosuppressive properties of certain opioid analgesics, including morphine and fentanyl, are well-established (15, 16). In animal models, exposure to particular opioids increased the risk for infections due to common pathogens, including S pneumoniae (19, 20) . In humans, opioid use previously was linked to an increased risk for infection among hospitalized surgical, burn, and cancer patients (37-39). Two previous studies also reported an association between outpatient prescription opioid use and the risk for serious infection in specific high-risk groups. One study, restricted to community-dwelling older adults enrolled in a private health insurance system, reported that patients with pneumonia were 39% more likely than control participants to have been exposed to opioids (13). The other study, in patients with rheumatoid arthritis, found that the frequency of hospitalization for serious infection increased 38% during periods of opioid use compared with nonuse, and the results were consistent across pneumonia and serious nonpneumonia infections (14). In both previous studies, and consistent with our current findings, serious infections occurred most frequently during periods of exposure to long-acting opioids, high opioid doses, and opioids previously described as immunosuppressive (13, 14) .
A unique strength of this study was the use of ABCs data to identify laboratory-confirmed IPD cases. We minimized misclassification by using only laboratoryconfirmed outcomes. The specificity of laboratoryconfirmed IPD is very high, supporting its use in assessing relative measures of association. Furthermore, IPD is a prototypical community-acquired infection and thus is less affected by other factors (such as recent hospitalization and intravenous drug use) that may affect evaluation of serious infections as a whole (26). In the context of the previous literature, our assessment of IPD complements previous studies and suggests that opioid analgesic use increases the risk for serious infections in humans (13, 14).
An important limitation was that opioid use was based on pharmacy prescription fills, but actual use ORIGINAL RESEARCH Opioid Use and Invasive Pneumococcal Disease Risk was not observed. We attempted to minimize misclassification of the exposure by defining recent and past use categories to ensure that the current use category represented periods with the highest likelihood of opioid use. Although we accounted for evidence of alcohol or substance use disorders in the analysis, we could not assess illicit opioid use. Another limitation was the inability to make direct comparisons across opioid types while accounting for duration of action, potency, and dosage of each opioid. Although we observed the strongest associations for long-acting, high-potency, immunosuppressive, and high-dose opioids, laboratoryconfirmed IPD was relatively rare, and our study was underpowered to account for these factors simultaneously and to make direct comparisons among individual opioids. Because the bioavailability, half-life, and amount of active metabolites differ among opioids, we would expect that the association between opioid use and serious infections might vary across agents. Future studies will be important to characterize the role of individual opioids and inform prescribers and patients regarding appropriate drug selection.
Our analyses accounted for several relevant covariates; however, we cannot rule out the possibility of residual confounding. We estimated that a potential unmeasured confounder would need to fulfill 2 criteria to explain our findings: be a very strong risk factor for IPD and have a substantial distribution imbalance between exposure groups. Nevertheless, the consistency of results in the more comprehensive IPD risk score analysis and the primary analysis should reduce concerns about residual confounding. Although our main analysis directly accounted for pneumococcal polysaccharide vaccination history during the year preceding the index date, an extended assessment also examined vaccination history during the 5 years preceding the index date and considered this a potentially unmeasured confounder. Because pneumococcal vaccination was more common among current than remote opioid users, accounting for the protective effect of this factor would result in a stronger association between opioid use and IPD. Likewise, we demonstrated that the availability of PCVs for adults starting in 2012 had no effect on our findings. Although our study covered several years, each case patient was matched on the index date to eligible at-risk control participants, so by design, comparisons accounted for changes in prescribing practices and disease incidence throughout the study period. This addressed concerns about the indirect protection derived from vaccination of infants with PCVs. Finally, because the study population consisted only of TennCare enrollees, the results may not be generalizable to other populations.
In conclusion, we found that current opioid use was strongly and consistently associated with the risk for IPD and that the association was strongest for the use of long-acting and high-potency formulations, opioids previously described as immunosuppressive, and highdose opioids. Our study findings complement the experimental evidence from animal models and initial studies in humans and indicate that prescription opioid use is an independent, novel risk factor for IPD. These findings should be considered when developing IPD prevention recommendations, including vaccination. Furthermore, this previously unrecognized association between opioid use and IPD highlights the need for judicious use of opioid analgesics that considers both the benefits and risks of these medications. Because the strongest associations were observed for opioids with certain characteristics, these findings should be considered when selecting opioid analgesics for pain management.
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Section 1. Calculation of IPD Risk Score
The IPD risk score, defined as the predicted probability of IPD, was calculated by using a logistic regression model for case patients and control participants who were noncurrent opioid users (that is, remote, past, and recent opioid users). The model initially included 106 variables, including demographic information, presence of conditions in the 365 days preceding the index date (comorbid conditions and surrogates of frailty), and the use of certain medications in the 365 days preceding the index date (Appendix Table 1 ). Well-recognized risk factors for IPD were not included in the infection risk score model, but relevant factors were accounted for directly in the final model, which also included exposures and the IPD risk score deciles (see later) (33-35).
Three variables were automatically dropped from the initial model, because no IPD cases with those conditions were identified. Overall, the number of participants with those conditions was very small (multiple sclerosis, personality disorders, and multiple system atrophy). No multicollinearity issues were identified. The results from the final IPD risk score, including 103 variables, are outlined in Appendix Table 2 . Using the coefficients from the logistic regression model predicting IPD among all noncurrent opioid users, we then calculated the predicted probability of IPD independent of opioid use (that is, the IPD risk score) for all persons in the study population. We then created 10 mutually exclusive categories based on the decile distribution of the IPD risk score among the entire study population. The results from a conditional logistic regression model with IPD as the outcome and including the main exposure variable, all well-recognized risk factors for IPD, and the categorical infection risk score (deciles) as covariates are presented in Appendix Table 5 .
Assessment of IPD Risk Score Model Fit
The Hosmer-Lemeshow test statistic for the model collapsed across deciles of the estimated IPD probabilities was 11.28 (P = 0.186), indicating that we could not reject the null hypothesis of good model fit and a lack of calibration error. In addition, we visually inspected the decile categorization of the infection risk score to ensure that the risk for IPD increased with increasing risk score deciles among both the unexposed and the full study population (Appendix Figure 3) .
In addition, to determine the appropriateness of the disease risk score approach, we assessed the correlation between the exposure and the confounders used in the disease risk score. It has been suggested that the disease risk score may perform poorly when the covariate-exposure OR is greater than 2.0 and when the squared multiple correlation coefficient between the exposure and individual confounders is greater than 0.9 (34). Simulation studies have demonstrated that aside from these infrequent scenarios, the disease risk score method performs reasonably well, even in the presence of moderate association between confounders and the exposure.
In our study, current opioid use did not have a correlation coefficient greater than 0.5 with any of the variables included in the IPD risk score. In addition, the IPD risk score (as a continuous variable) was not strongly associated with being a current opioid user in the study population (OR, 1.05), nor was it associated with being a current opioid user when categorized into deciles (the highest ORs in the 2 highest decile categories-1.20 and 1.42, respectively-were still not strongly associated with exposure). A few variables had a weak or moderate correlation with opioid use (correlation coefficient >0.2), including bariatric surgery, back pain, disease-modifying antirheumatic drug history, neuropathic pain, drug poisoning, smoking cessation products, and peripheral neuropathy. However, if these variables were removed from the IPD risk score calculation and instead included individually in the full model with all well-recognized risk factors for IPD and the updated IPD risk score, the aOR was very similar to results from the primary analysis: 1.66 (CI, 1.39 to 1.99). Therefore, the modest association observed between the IPD risk score and current opioid use probably did not affect our aOR substantially. In addition, although a few covariates in the IPD risk score had a moderate to high correlation with the exposure (current opioid use), including them in the infection risk score did not substantially change the observed aOR compared with including these covariates in the final outcome model instead.
Section 2. Expanded Results From Primary Analysis
In the primary analysis, all well-recognized risk factors for IPD were identified a priori and measured in the 365 days preceding the index date for case patients and control participants. In accordance with the Advisory Committee on Immunization Practices, these variables included diagnoses of certain conditions, including alcohol or substance use disorder, cardiovascular disease, serious hepatic or chronic lung disease, endstage renal disease, HIV, cancer, immune disorders or transplantation, diabetes, sickle cell disease, and tobacco smoking, as well as health care encounter history, including pneumococcal vaccination history, recent nursing home stay (past 30 days), and the number of hospitalizations and outpatient and emergency department visits in the past year (22-25).
All well-recognized risk factors for IPD were identified by using study covariates according to the definitions in Appendix Table 1 . The results from the full conditional logistic regression model, including opioid exposure and all well-recognized risk factors for IPD (primary analysis), are presented in Appendix Table 3 . The results from each of the full conditional logistic regression models stratifying current opioid use on the basis of the characteristics of the opioid are presented in Appendix Table 4 .
Section 3. Regression Diagnostics and Assessment of Model Fit
We verified the fulfillment of our conditional logistic regression model assumptions (32). Three plots were used to visually identify any outliers by using diagnostic statistics for each observation (see the following descriptions). Outliers were identified as any observations with values that were very different from the distribution of values for the study population as a whole in the following scatter plots:
1. Hosmer-Lemeshow leverage statistic versus estimated probability from the fitted model for each observation.
2. Change in Pearson chi-square statistic versus estimated probability from the fitted model for each observation.
3. Change in deviance statistic versus estimated probability from the fitted model for each observation.
Overall, the plots showed that the model fit the data well. Few observations were identified as outliers on the basis of the leverage and change in deviance statistic for each observation or for each matched group. No outlier observations were identified in the plot of the change in Pearson chi-square statistic for each observation or for each matched group, although calculated values were relatively higher among case patients than control participants in the plot of individual observations. In sensitivity analyses excluding observations with a change in Pearson chi-square statistics greater than 50, the association between current opioid use and IPD was consistent (aOR, 1.81 [CI, 1.51 to 2.17]) with the main study finding, although the point estimate was even higher.
Section 4. Sensitivity Analysis to Determine the Amount of Residual Confounding Required to Explain Observed Association
Because uncontrolled confounding, especially residual confounding, is an important concern in epidemiologic studies, we conducted a sensitivity analysis to explore the strength of association and distribution of a hypothetical binary unmeasured confounder that would be required in the association between opioid use and the risk for IPD to explain the observed aOR of 1.62 (CI, 1.36 to 1.92). To conduct this sensitivity analysis, we used an array approach to determine how different assumptions about an unmeasured confounder might explain the observed association in our primary analysis (36). The analysis can be conducted by using a worksheet freely available at www.drugepi.org.
For a conservative assessment, we focused on the lower bound of the 95% CI from our main analysis as the "observed" OR in our study, an aOR of 1.36. We then determined the "true" OR that would exist if a certain unmeasured confounder that was not accounted for in our study had been accounted for subsequently. This assessment involved varying the prevalence of the hypothetical unmeasured confounder in the exposed (current opioid users) and unexposed (remote opioid users) groups, as well as the strength of the association between the hypothetical unmeasured confounder and IPD. We examined different scenarios, varying the prevalence of the confounder in current opioid users from 0% to 50% but holding the prevalence constant in remote opioid users at 10% and 20%, as well as varying the strength of the confounder-IPD association from 1.0 to 5.5.
On the basis of those assumptions, we estimated that an unmeasured confounder would have to be an independent, strong risk factor for IPD, with an OR of 2 or higher, and need to have an absolute difference in prevalence of 35% or greater between current and remote opioid users to explain the observed aOR of 1.36 (Appendix Figure 2) .
As an example of how to interpret Appendix Figure  2 , the dark blue distribution represents the different unmeasured confounder scenarios to explain a true OR between 0.6 and 0.8, whereas the light blue distribu-tion represents scenarios with a true OR between 0.8 and 1.0. The red circles represent a true OR of 1.0, which would occur, for example, in a scenario in which the unmeasured confounder had a prevalence of 30% among current opioid users (20% prevalence difference) and an OR of 3.0 for IPD, whereas we observed an OR of 1.36 without accounting for that unmeasured confounder.
At other absolute differences in prevalence (25%, 15%, and 10%), the unknown confounder would need to have a stronger, independent association with IPD (ORs of 2.5, 3.5, and 5.5, respectively). Weaker confounders or those with lower exposure prevalence differences could attenuate the observed association only partially but could not fully account for it (Appendix Figure 2) . The estimations used to create Appendix Figure 2 may be replicated by using a worksheet freely available at www.drugepi.org (36).
Of importance, none of the measured covariates (including well-known risk factors for IPD) included in our study met any of the scenarios previously described ( Table 4 and Appendix Table 3 ). The greatest independent associations between a risk factor and IPD were for HIV, sickle cell disease, and serious hepatic disease (aOR, 10.22, 3.75, and 2.94, respectively). Yet, these conditions are rare, with an absolute difference in prevalence between current and remote opioid users of 0.9%, 0.2%, and 1.2%, respectively ( Table 4) . The greatest absolute prevalence differences between current and remote opioid users were found with regard to race (23.6% in whites), number of outpatient visits (25.1% in those visiting outpatient settings 10 to 19 times in the previous year), chronic lung disease (14.8%), smoking and smoking-related diagnoses (11.9%), diabetes (10.8%), cardiovascular disease (10.5%), and age (10.1% in adults aged 40 to 64 years). Yet, these covariates had aORs of less than 1.83 for IPD and were all fully accounted for by our design and analyses.
In addition, the more comprehensive IPD risk score analysis found results that were virtually identical to those of the primary analysis. Because the IPD risk score included all measured relevant covariates, unmeasured confounding probably cannot explain the entire observed association between opioid use and the risk for IPD.
Section 5. Power Analysis Conducted at Study Initiation
We conducted an a priori power analysis before initiating the study. On the basis of preliminary assessments of opioid use in the TennCare population, we assumed that 15% to 30% of TennCare enrollees received an opioid at a given point during the study period. Given this possible distribution of current opioid use, and that we expected 500 to 2500 case patients, a nested case-control study design with 20 control participants matched to 1 case patient was estimated to have 80% power to detect an OR from 1.15 to 1.4 when comparing current use among case patients and control participants. Therefore, we determined that our study would have good power to detect a small association between current opioid analgesic use and the risk for IPD. In a post hoc power analysis, we found that with 1233 cases, the analysis had 80% power to detect an OR between 1.2 and 1.3. All estimations were done with Stata/IC, version 15.1, with an alpha of 0.05 and a power of 0.80. Male vs. female Female ‡ 1.90 aOR = adjusted odds ratio; ED = emergency department; IPD = invasive pneumococcal disease; IS = immunosuppressive; MME = morphine milligram equivalents; NIS = nonimmunosuppressive.
Appendix
* aORs are derived from full models including all the covariates listed in the table, taking into account the study design, in which control participants were matched to case patients by age, county of residence, and eligibility on the index date (i.e., control participants had to be eligible members of the retrospective cohort on the index date for the case). † Opioid use was assessed relative to the index date for case patients and matched control participants. ‡ Reference category for comparison. § Comorbid conditions and health care use patterns were assessed in the 365-d period preceding the index date for case patients and control participants (with the exception of "recent stay at nursing home stay").
͉͉ Pneumococcal polysaccharide vaccination. ¶ Recent nursing home stay assessed in the 30-d period preceding the index date for case patients and control participants. ** Because >75% of participants had ≥1 outpatient visit, the reference category for this comparison was set at 0 -4 outpatient visits in the past year. among remote opioid users at 10%. The figure represents different scenarios in which a hypothetical unmeasured confounder could have influenced the observed aOR in the primary analysis. We used the lower bound of the CI of the aOR in the primary analysis for a conservative assessment of these scenarios: aOR, 1.36. For all scenarios in the figure, we assume that the prevalence of the unmeasured confounder is 10% among remote opioid users, our reference. The y-axis represents the absolute difference in prevalence of the unmeasured confounder between current and remote opioid users, whereas the x-axis represents different values of the OR representing the association between the unmeasured confounder and IPD. The colored bar represents the true OR we would expect to see under different unmeasured confounder scenarios. Thus, the true aOR would be <1 in all scenarios represented by the dark blue and light blue areas at the upper right of the figure. The red dots represent the unmeasured confounder scenarios at which a true aOR of 1.0 would be observed. For example, the red dot at the connecting point of 5.5 on the x-axis and 10 on the y-axis represents the following scenario: The true OR would be 1.0 if the observed aOR were 1.36 in the presence of unmeasured confounding from a variable that has a very strong association with IPD (OR, 5.5) and with a 10% absolute difference in prevalence between current and remote opioid users. For a confounder with a much weaker association with IPD (red dot at OR of 2.0), the absolute difference in prevalence of the confounder would need to be >35%. aOR = adjusted odds ratio; IPD = invasive pneumococcal disease; OR = odds ratio.
